Economic news

J&J to Buy Eye Disease Biotech Ollin for Up to $3.3B

  • Deal gives J&J access to eye drug candidate OLN324
  • Blackstone to provide $750 mln for OLN324 late-stage development
  • Ollin plans late-stage OLN324 trials this year

Nov 16 (Reuters) - Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies.

Ollin's experimental eye disease treatment, ​OLN324, will help J&J strengthen its presence in an area where ​it has a limited footprint, despite its large contact lens business.

OLN324 ⁠is being developed to treat diabetic macular edema (DME) and wet age-related macular ​degeneration (AMD), two leading causes of vision loss. Together, they affect more than 40 ​million people worldwide, J&J estimated.

"Johnson & Johnson has established strong credentials in ophthalmology with surgical vision equipment and vision care (primarily ACUVUE contact lenses), making this a logical strategic fit," said RBC ​Capital Markets analyst Trung Huynh.

In a recent early-stage head-to-head study, the drug ​showed faster and greater improvements in eye structure and greater vision gains in both DME ‌and ⁠wet AMD than Roche's Vabysmo, Ollin said.

The buyout includes an upfront $2.2 billion and potential regulatory and commercial milestone payments of up to $1.13 billion, J&J said. It is expected to close by year-end.

Ollin, backed by investment firms ARCH Venture ​Partners and Mubadala Capital, ​was established ⁠in 2023 to develop treatments for vision-threatening diseases. Its pipeline includes OLN102, currently in preclinical development, for thyroid eye disease ​and Graves' disease.

The biotech raised $330 million in June to fund ​late-stage trials ⁠of OLN324.

J&J also said it would enter into a separate agreement with Blackstone Life Sciences for a $750 million multi-year funding for the late-stage development of OLN324, in ⁠exchange for ​some payments and royalties.

Last week, Pfizer said Blackstone would provide ​up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.

Reporting ​by Sneha S K in Bengaluru; Editing by Anil D'Silva and Joyjeet Das

Source: Reuters


To leave a comment you must or Join us


More news


Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree